Phase II Study of Panobinostat (LBH589) for Recurrent Glioblastoma (GBM) Undergoing Planned Surgical Resection.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Panobinostat (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
Most Recent Events
- 11 Oct 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 May 2010 New trial record